查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1880669

腸外抗生素市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Parenteral Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 186 Pages | 商品交期: 請詢問到貨日

價格

腸外抗生素市場成長推動因素

隨著醫院和重症監護機構越來越依賴靜脈注射 (IV) 和肌肉注射 (IM) 抗生素製劑來治療嚴重感染，全球腸外抗生素市場持續擴張。最新評估顯示，受住院人數增加、多重抗藥性感染流行以及腸外抗生素在重症監護環境中廣泛使用等因素驅動，該市場在 2024 年的規模將達到 242.2 億美元。預計到 2025 年，該市場規模將成長至 250.9 億美元，長期預測到 2032 年將達到 336.6 億美元，預測期內複合年增長率 (CAGR) 為 4.3%。

北美將繼續維持其主導地位，到2024年將佔全球市場45.5%的佔有率（價值110.2億美元）。該地區強大的臨床基礎設施、先進的診斷能力以及在重症監護環境中頻繁使用腸外療法，持續推動市場需求的成長。輝瑞、葛蘭素史克、艾伯維、默克、拜耳和百時美施貴寶等全球主要公司正透過產品上市、仿製藥擴張和抗菌藥物創新，在塑造市場趨勢方面發揮關鍵作用。

市場動態

市場推動因素

市場成長的主要推動因素是因肺炎、敗血症、腦膜炎、泌尿道感染和手術部位感染等嚴重感染而住院率的上升。醫院獲得性感染（HAI）顯著增加了對腸外療法的需求，尤其是在重症監護病房。根據世界衛生組織的數據，全球十分之一的住院患者會感染醫院獲得性感染，顯示人們對腸外抗生素的依賴性日益增強。

另一個重要的推動因素是免疫功能低下患者數量的增加，例如癌症患者、移植患者和愛滋病毒/愛滋病患者，他們需要快速、有效率的抗生素幹預。門診靜脈抗生素治療（OPAT）的出現也促進了市場擴張，使患者能夠在傳統醫院環境之外接受靜脈抗生素治療。

市場限制因子

新興市場抗生素的取得障礙阻礙了市場成長。醫療基礎設施薄弱、冷鏈設施有限以及高昂的自付費用降低了高品質注射藥物的可及性。對特定國家活性藥物成分（API）的依賴使全球供應鏈面臨供應中斷和價格波動的風險。

此外，抗生素研發的低利潤率仍然是一個挑戰。療程短、使用限制嚴格以及監管流程限制了製藥業的投資回報，並阻礙了創新。

市場機會

門診抗生素治療 (OPAT) 計畫的快速發展為提供經濟高效的腸外抗生素提供了巨大的機會。研究表明，與住院治療相比，OPAT 可降低 22% 至 42% 的治療成本，同時提高患者舒適度並釋放醫院資源。支付方對 OPAT 的支持力度加大以及家庭醫療保健模式的興起，將為製造商創造新的收入機會。

市場挑戰

腸外抗生素的監管壁壘和複雜的批准要求延長了研發週期並增加了生產成本。此外，全球範圍內減少不必要抗生素使用的努力可能會限制某些地區的銷售量成長。

主要區隔市場特徵

依藥物類別

截至2024年，青黴素類藥物憑藉其廣泛的可及性、臨床療效和不斷提高的仿製藥滲透率，佔市場主導地位。頭孢菌素類藥物也將繼續保持較大的市場佔有率，因為它們在多種感染類型中具有廣泛的臨床應用。預計到2032年，大環內酯類、氟喹諾酮類和氨基糖苷類藥物的市佔率將穩定成長。

依應用領域

2024年，呼吸道感染領域佔最大的市場佔有率，這主要得益於肺炎、結核病和鼻竇炎病例的增加。泌尿道感染（UTI）領域緊隨其後，這得益於針對複雜性泌尿道感染和醫院獲得性病原體的產品上市。

依分銷管道

截至2024年，醫院藥局在靜脈注射抗生素的管理中發揮核心作用，佔市場主導地位。由於數位化進程的推進和家庭醫療保健的普及，預計線上藥局領域將實現最快成長。

區域洞察

北美

北美市場預計將在2024年達到110.2億美元，憑藉強有力的抗生素管理計劃、先進的診斷技術以及創新註射藥物的快速普及，預計將繼續保持領先地位。

歐洲

歐洲則位居第二，這得益於較高的抗生素使用率和強而有力的監管。製造商之間的合作關係不斷鞏固市場地位。

亞太地區

預計亞太地區將實現最快成長。注射用抗生素獲批數量的增加、高傳染病負擔以及龐大的人口規模正在推動該地區的需求增長。

拉丁美洲、中東和非洲

隨著宣傳活動的擴展和政府抗生素指南的加強，預計這些地區的需求將出現溫和增長。

如果您需要，我們也提供SEO優化的HTML版本、詳細的區域分析或依藥物類別進行的比較分析。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家/地區主要疾病盛行率（2024 年）
  • 主要國家的報銷情況
  • 主要公司產品線分析
  • 概述：腸外抗生素給藥技術進展
  • 主要公司新產品發布
  • 主要產業趨勢，包括併購和合作夥伴關係

第五章：全球注射用抗生素市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依藥物類別劃分
    • 青黴素類
    • 頭孢菌素類
    • 氨基糖苷類
    • 四環素類
    • 大環內酯類
    • 氟喹諾酮類
    • 磺胺類
    • 其他
  • 市場分析、洞察與預測 - 依應用領域劃分
    • 皮膚感染
    • 呼吸道感染
    • 泌尿道感染
    • 敗血症
    • 胃腸道感染
    • 其他
  • 市場分析、洞察與預測 - 依銷售額分割管道
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美注射腸外抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲注射腸外抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國王國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區注射抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲注射抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東和非洲注射抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 百時美施貴寶公司
    • 輝瑞公司
    • 山德士集團
    • 葛蘭素史克公司
    • 拜耳股份公司
    • 默克公司
    • 西普拉製藥
    • 艾伯維公司
    • 艾德瓦凱製藥
Product Code: FBI113796

Growth Factors of parenteral antibiotics Market

The global parenteral antibiotics market continues to expand as hospitals and critical care centers increasingly rely on intravenous (IV) and intramuscular (IM) antibiotic formulations to manage severe infections. According to the latest assessment, the market was valued at USD 24.22 billion in 2024, driven by rising hospital admissions, increasing prevalence of multidrug-resistant infections, and the widespread use of injectable antibiotics in emergency care. In 2025, the market is projected to grow to USD 25.09 billion, while long-term forecasts indicate a rise to USD 33.66 billion by 2032, reflecting a CAGR of 4.3% during the forecast period.

North America held the dominant market position in 2024, accounting for 45.5% of global revenue, equivalent to USD 11.02 billion. The region's strong clinical infrastructure, high diagnostic capabilities, and frequent use of parenteral therapies in intensive care settings continue to fuel demand. Major global companies-including Pfizer Inc., GSK plc, AbbVie Inc., Merck & Co., Inc., Bayer AG, and Bristol-Myers Squibb Company-play a significant role in shaping market performance through product launches, generic expansion, and antimicrobial innovation.

Market Dynamics

Market Drivers

A key driver of market growth is the increasing rate of hospitalizations due to severe infections, including pneumonia, septicemia, meningitis, urinary tract infections, and surgical site infections. Hospital-acquired infections (HAIs) significantly contribute to the need for parenteral therapy, especially in critical care units. According to WHO, 1 in 10 hospitalized patients worldwide is affected by HAIs, underscoring the growing reliance on injectable antibiotics.

Another strong driver is the rising population of immunocompromised patients, including cancer patients, transplant recipients, and individuals with HIV/AIDS-groups that often require rapid, high-potency antibiotic intervention. The emergence of Outpatient Parenteral Antibiotic Therapy (OPAT) also contributes to market expansion, enabling patients to receive intravenous antibiotics outside traditional hospital settings.

Market Restraints

Growth is hampered by barriers to antibiotic access in emerging markets. Weak healthcare infrastructure, limited cold-chain facilities, and high out-of-pocket expenses reduce the availability of quality parenteral medications. Dependence on select countries for active pharmaceutical ingredients (APIs) makes global supply chains vulnerable to disruptions and price fluctuations.

Additionally, the low profitability of antibiotic research and development remains a challenge. Short treatment durations, stewardship-driven restrictions, and rigorous regulatory pathways limit returns on investment, discouraging pharmaceutical innovation.

Market Opportunities

The rapid expansion of OPAT programs presents major opportunities for cost-effective parenteral antibiotic delivery. Studies have shown that OPAT can reduce treatment costs by 22%-42% compared to inpatient care, while improving patient comfort and freeing hospital resources. Growing payer support for OPAT and the rise of home-based healthcare models will create new revenue openings for manufacturers.

Market Challenges

Regulatory hurdles and complex approval requirements for injectable antibiotics prolong development timelines and increase production costs. Additionally, global efforts to reduce unnecessary antibiotic use may limit volume growth in certain regions.

Segmentation Highlights

By Drug Class

Penicillin led the market in 2024, supported by its broad availability, clinical effectiveness, and growing generic penetration. Cephalosporins also maintained a significant share due to their wide clinical application across multiple infection types. Macrolides, fluoroquinolones, and aminoglycosides are expected to record steady growth through 2032.

By Application

The respiratory infections segment held the largest share in 2024, driven by rising cases of pneumonia, tuberculosis, and sinusitis. The urinary tract infections (UTI) segment follows, supported by product introductions targeting complicated UTIs and hospital-acquired pathogens.

By Distribution Channel

Hospital pharmacies dominated the market in 2024 due to their central role in administering IV antibiotics. The online pharmacy segment is projected to grow fastest as digital adoption increases and home-based care expands.

Regional Insights

North America

Valued at USD 11.02 billion in 2024, North America will maintain leadership with strong antimicrobial stewardship programs, advanced diagnostics, and rapid adoption of innovative injectables.

Europe

Europe ranked second, supported by high antibiotic usage rates and strong regulatory oversight. Collaborative partnerships among manufacturers continue to strengthen the market landscape.

Asia Pacific

Asia Pacific is expected to grow at the fastest rate. Increasing approvals for injectable antibiotics, high infection burdens, and large populations accelerate regional demand.

Latin America & Middle East-Africa

These regions are poised for moderate growth as awareness programs expand and governments strengthen antimicrobial guidelines.

Conclusion

Growing from USD 24.22 billion in 2024 to USD 33.66 billion by 2032, the parenteral antibiotics market remains essential for managing severe infections worldwide. Rising HAIs, the adoption of OPAT, and expanding generic manufacturing will continue to shape market evolution over the next decade.

If you want, I can also prepare an SEO-optimized HTML version, regional deep-dive, or drug-class comparative analysis.

Segmentation By Drug Class

  • Penicillin
  • Cephalosporin
  • Aminoglycosides
  • Tetracycline
  • Macrolides
  • Fluoroquinolones
  • Sulfonamides
  • Others

By Application

  • Skin Infections
  • Respiratory Infections
  • Urinary Tract Infections
  • Septicemia
  • Gastrointestinal Infections
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2024
  • 4.2. Reimbursement Scenario, By Key Countries/Regions
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview: Technological Advancements in Parenteral Antibiotics Delivery
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Penicillin
    • 5.1.2. Cephalosporin
    • 5.1.3. Aminoglycosides
    • 5.1.4. Tetracycline
    • 5.1.5. Macrolides
    • 5.1.6. Fluoroquinolones
    • 5.1.7. Sulfonamides
    • 5.1.8. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Skin Infections
    • 5.2.2. Respiratory Infections
    • 5.2.3. Urinary Tract Infections
    • 5.2.4. Septicemia
    • 5.2.5. Gastrointestinal Infections
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail Pharmacy
    • 5.3.3. Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Penicillin
    • 6.1.2. Cephalosporin
    • 6.1.3. Aminoglycosides
    • 6.1.4. Tetracycline
    • 6.1.5. Macrolides
    • 6.1.6. Fluoroquinolones
    • 6.1.7. Sulfonamides
    • 6.1.8. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Skin Infections
    • 6.2.2. Respiratory Infections
    • 6.2.3. Urinary Tract Infections
    • 6.2.4. Septicemia
    • 6.2.5. Gastrointestinal Infections
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail Pharmacy
    • 6.3.3. Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Penicillin
    • 7.1.2. Cephalosporin
    • 7.1.3. Aminoglycosides
    • 7.1.4. Tetracycline
    • 7.1.5. Macrolides
    • 7.1.6. Fluoroquinolones
    • 7.1.7. Sulfonamides
    • 7.1.8. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Skin Infections
    • 7.2.2. Respiratory Infections
    • 7.2.3. Urinary Tract Infections
    • 7.2.4. Septicemia
    • 7.2.5. Gastrointestinal Infections
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Penicillin
    • 8.1.2. Cephalosporin
    • 8.1.3. Aminoglycosides
    • 8.1.4. Tetracycline
    • 8.1.5. Macrolides
    • 8.1.6. Fluoroquinolones
    • 8.1.7. Sulfonamides
    • 8.1.8. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Skin Infections
    • 8.2.2. Respiratory Infections
    • 8.2.3. Urinary Tract Infections
    • 8.2.4. Septicemia
    • 8.2.5. Gastrointestinal Infections
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Penicillin
    • 9.1.2. Cephalosporin
    • 9.1.3. Aminoglycosides
    • 9.1.4. Tetracycline
    • 9.1.5. Macrolides
    • 9.1.6. Fluoroquinolones
    • 9.1.7. Sulfonamides
    • 9.1.8. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Skin Infections
    • 9.2.2. Respiratory Infections
    • 9.2.3. Urinary Tract Infections
    • 9.2.4. Septicemia
    • 9.2.5. Gastrointestinal Infections
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Penicillin
    • 10.1.2. Cephalosporin
    • 10.1.3. Aminoglycosides
    • 10.1.4. Tetracycline
    • 10.1.5. Macrolides
    • 10.1.6. Fluoroquinolones
    • 10.1.7. Sulfonamides
    • 10.1.8. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Skin Infections
    • 10.2.2. Respiratory Infections
    • 10.2.3. Urinary Tract Infections
    • 10.2.4. Septicemia
    • 10.2.5. Gastrointestinal Infections
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Bristol-Myers Squibb Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Sandoz Group AG
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. GSK plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bayer AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Cipla
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AbbVie Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. AdvaCare Pharma
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 2: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 3: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 6: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 7: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 10: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 11: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 14: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 15: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 18: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 19: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 22: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 23: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Parenteral Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024 & 2032
  • Figure 3: Global Parenteral Antibiotics Market Value Share (%), By Application, 2024 & 2032
  • Figure 4: Global Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Parenteral Antibiotics Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 7: North America Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 8: North America Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 9: North America Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 10: North America Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Parenteral Antibiotics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Parenteral Antibiotics Market Value Share (%), By Country, 2024
  • Figure 14: Europe Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 15: Europe Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 16: Europe Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 17: Europe Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 18: Europe Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 23: Asia Pacific Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 24: Asia Pacific Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 25: Asia Pacific Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 26: Asia Pacific Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 31: Latin America Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 32: Latin America Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 33: Latin America Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 34: Latin America Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 39: Middle East & Africa Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 40: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 41: Middle East & Africa Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 42: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Parenteral Antibiotics Market Share (%), By Company, 2024